Drug intelligence / Profile preview

Panadol Osteo

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

**Panadol Osteo** is a modified-release, bi-layer caplet formulation containing **665 mg paracetamol** per tablet, designed for prolonged pain relief. It combines an immediate-release layer for rapid onset and a sustained-release layer using hypromellose polymer for diffusion and erosion-controlled release, maintaining therapeutic plasma levels up to 8 hours. Primarily indicated for persistent pain in **osteoarthritis** and muscle aches like backache, it also provides temporary relief for headache, tension headache, period pain, toothache, colds, flu, and reduces fever. Paracetamol acts centrally to inhibit pain signal transmission to the brain and reduce fever, with bioequivalence to standard immediate-release paracetamol at steady state but lower peak-trough fluctuations for consistent analgesia. Available over-the-counter in Australia and New Zealand as a pharmacist-only medicine (S3), dosed as 2 caplets three times daily (max 6/24h) for adults/children ≥12 years, swallowed whole orally.[1][2][5][9]

Brand names
Panadol Osteo
Other names
acetaminophen sustained releaseparacetamol SRAPAP SR
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Panadol Osteo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panadol Osteo.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call